Quarterly ResultMay 15, 2026, 07:32 AM
Annovis Bio AD Trial 85% Enrolled; NDA Expected Early 2027
AI Summary
Annovis Bio provided business updates and Q1 2026 financial results, highlighting significant progress in its clinical programs. The Phase 3 Alzheimer's disease (AD) trial is 85% enrolled and on track for full enrollment by summer 2026, with NDA submissions for symptomatic and disease-modifying AD expected in early 2027 and early 2028, respectively. The Parkinson's disease (PD) open-label extension study is 40% enrolled, targeting full enrollment by Q4 2026. The company reported cash and equivalents of $14.2 million as of March 31, 2026, and a net loss per share of $(0.63) for the quarter.
Key Highlights
- Phase 3 AD trial 85% enrolled; full enrollment expected summer 2026.
- PD open-label extension study 40% enrolled; full enrollment expected Q4 2026.
- NDA for symptomatic AD expected early 2027; disease-modifying AD early 2028.
- Positive Data and Safety Monitoring Board recommendation for AD trial safety at 6 months.
- Cash and cash equivalents totaled $14.2 million as of March 31, 2026.
- Q1 2026 R&D expenses were $16.7 million, up from $5.0 million in Q1 2025.
- Q1 2026 net loss per common share was $(0.63), compared to $(0.32) in Q1 2025.
Price Impact
More from ANVS